Elucid Bioimaging

Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based arterial analysis software.

Launch date

2013

Employees

Market cap

Enterprise valuation

Boston Massachusetts (HQ)

Date	Investors	Amount	Round
-	Checkmate Capital Group Checkmate Capital	N/A	-
Aug 2013	N/A	$380k	Seed
Mar 2014*	National Science Foundation	$1.4m	Grant
Jan 2015	Small Business Innovation Research (SBIR)	$1.6m	Grant
Jan 2016	N/A	$1.0m	Seed
Aug 2016	N/A	$5.0m	Seed
Jun 2019	N/A	$3.0m	Grant
May 2021	Wolverine Venture Fund Checkmate Capital BlueStone Venture Partners IAG Capital Partners Willamette Valley Capital Angel Physician Fund MedTex Ventures Global Health Impact Fund	$8.0m	Series A
Jun 2022*	BlueStone Venture Partners IAG Capital Partners MedTex Ventures Bold Brain Ventures Biovision Ventures	$27.0m	Series B
Mar 2023	Aphelion Capital BlueStone Venture Partners IAG Capital Partners Bold Brain Ventures Biovision Ventures	$27.0m	Series B
Nov 2023*	Elevage Medical Technologies	$80.0m	Series C
Total Funding		€141m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Elucid Bioimaging